Characterization of molecular mechanisms of acquired resistance to Trastuzumab in gastric cancer 

Sampera Borràs, Aïda (Date of defense: 2018-11-20)

The HER2 receptor is overexpressed in 7-34% of gastric cancer (GC) tumors, being a potential therapeutic target. Trastuzumab, an anti-HER2 monoclonal antibody, in combination with platinum therapy was approved in 2010 as ...